docetaxel anhydrous has been researched along with Inflammatory Breast Neoplasms in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirai, A; Ichiki, Y; Imanishi, N; Ishida, T; Kusanagi, K; Shinohara, S; Takeda, Y; Tanaka, F; Tashima, Y; Yoshimatsu, K | 1 |
| Andre, F; Chan, A; Chan, S; Gianni, L; Greil, R; Lichinitser, M; Lipatov, O; Mansutti, M; Mariani, P; Moore, N; Pallaud, C; Pivot, X; Prot, S; Romieu, GH; Semiglazov, V; Serrano, SV; Wardley, A | 1 |
| Chia, S; Cortés, J; Eniu, A; Harvey, V; Hegg, R; Hickish, T; McNally, V; Ratnayake, J; Ross, G; Schneeweiss, A; Seo, JH; Tausch, C; Tsai, YF | 1 |
| Inoue, K; Sonoda, T; Tsubamoto, H | 1 |
| Bachelot, T; Bidard, FC; Bonneterre, J; Campone, M; Charafe-Jauffret, E; Ferrero, JM; Gligorov, J; Hernandez, J; Lerebours, F; Lévy, C; Petit, T; Pierga, JY; Roché, H; Viens, P | 1 |
| Bachelot, T; Boher, JM; Delva, R; Dohollou, N; Eymard, JC; Fabbro, M; Ferrero, JM; Gonçalves, A; Leduc, B; Lemonnier, J; Lerebours, F; Linassier, C; Lotz, JP; Martin, AL; Mouret-Reynier, MA; Pierga, JY; Roché, H; Viens, P | 1 |
| Andre, F; Autret, A; Bachelot, T; Bertucci, F; Bidard, FC; Boher, JM; Bonneterre, J; Campone, M; Charafe-Jaufret, E; Dalenc, F; Eymard, JC; Ferrero, JM; Gligorov, J; Hardy-Bessard, AC; Kerbrat, P; Lemonnier, J; Lerebours, F; Levy, C; Lortholary, A; Mouret-Reynier, MA; Petit, T; Pierga, JY; Proudhon, C; Romieu, G; Soulie, P; Viens, P | 1 |
| Czeglédi, F; Eckhardt, S; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Kásler, M; Láng, I; Polgár, C; Torday, L; Urbán, L | 1 |
| Crane, K | 1 |
| Anan, K; Ikejiri, K; Kudaka, M; Kuroki, S; Mitsuyama, S; Nakafusa, Y; Namba, K; Nishimura, R; Ohchi, T; Oikawa, T; Rai, Y; Saimura, M; Tamura, K; Toyoshima, S | 1 |
| Bartlett, J; Bogaerts, J; Bonnefoi, H; Cameron, D; Debled, M; Fiche, M; Fournier, M; Koch, KM; Marreaud, S; Nobahar, M; Pierga, JY; Zaman, K; Zimmer, A | 1 |
6 trial(s) available for docetaxel anhydrous and Inflammatory Breast Neoplasms
| Article | Year |
|---|---|
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Hypertension; Inflammatory Breast Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Quality of Life; Receptor, ErbB-2; Surveys and Questionnaires; Taxoids; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Heart; Humans; Inflammatory Breast Neoplasms; Neoadjuvant Therapy; Receptor, ErbB-2; Stroke Volume; Taxoids; Trastuzumab; Ventricular Function, Left | 2013 |
Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Prognosis; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab | 2015 |
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2015 |
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Prognosis; Receptor, ErbB-2; Taxoids; Trastuzumab; Young Adult | 2017 |
An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Taxoids | 2013 |
5 other study(ies) available for docetaxel anhydrous and Inflammatory Breast Neoplasms
| Article | Year |
|---|---|
[A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Cilostazol; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Combinations; Epirubicin; Factor Xa Inhibitors; Fatal Outcome; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Male; Oxonic Acid; Pyridines; Radiotherapy, Intensity-Modulated; Skin Neoplasms; Syndrome; Tegafur; Thiazoles; Thrombophilia | 2019 |
Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Inflammatory Breast Neoplasms; Itraconazole; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Triple Negative Breast Neoplasms | 2014 |
Inflammatory breast cancer-comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Docetaxel; Epirubicin; Female; Follow-Up Studies; Humans; Inflammatory Breast Neoplasms; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Elucidating an uncommon disease: inflammatory breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diagnosis, Differential; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Mastitis; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2; Remission Induction; Taxoids; Transforming Growth Factor beta; Trastuzumab; Treatment Outcome | 2011 |
[A multicenter study of epirubicin-docetaxel(ET)as primary chemotherapy for patients with inflammatory breast cancer(IBC)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Taxoids | 2012 |